23 Jul, 2026
According to Straits Research, the global mRNA vaccines and therapeutics market size was valued at $62.91 billion in 2025 and is projected to grow from $73.55 billion in 2026 to $256.7 billion by 2034, registering a CAGR of 16.91% during the forecast period 2026–2034.
mRNA-based therapeutics and vaccines permit the combination of desirable immunological properties. These are manufactured in the laboratory using mammalian cells and injected into the target to activate virus-detecting immune sensors and produce viral antigen proteins within the cells. This strengthens the immune system by enhancing B- and T-cell responses. As the COVID-19 pandemic shows no signs of abating, healthcare agencies and governments worldwide are implementing stringent preventive measures to prevent more illnesses. Pharmaceutical companies worldwide are in a race against time to develop messenger ribonucleic acid (mRNA)-based COVID-19 vaccines that are highly safe, productive, and reliable in terms of clinical outcome, as vaccination is now the most viable method for preventing SARS-CoV-2 infection among the general population.
Growing Cases of COVID-19 Drive the Global Market
COVID-19 is caused by the SARS-CoV-2 virus, which emerged in December 2019 in Wuhan, China. Through direct or indirect human-to-human transmission, the SARS-CoV-2 virus is readily accessible and transferable. Due to the highly contagious nature of the virus, the infection rate is astronomical, resulting in a global increase in COVID-19 cases. In addition, the high infection rate of this virus has resulted in a pandemic, which has become one of the most significant humanitarian concerns in recent years. With a sharp increase in COVID-19 patients, there is an urgent need for effective vaccines through restarting vaccine development. Due to the advantages offered by mRNA-based COVID-19 vaccines and the rising incidence of COVID-19 worldwide, the demand for these vaccines has skyrocketed over the past few months, which is anticipated to fuel the expansion of the underlying global mRNA vaccines and therapeutics market over the next few years.
Growing Emphasis on Research and Development for Non-COVID-19 Applications Creates Tremendous Opportunities
The underlying molecular pathways related to the appearance and advancement of cancer, uncommon diseases, and immunological diseases have been intensively explored to develop new treatments. The emergence of mRNA-based vaccines and therapies is becoming a promising platform for developing novel treatments due to several advantages, including the efficiency of expressing tumor antigens in antigen-presenting cells (APCs), the induction of an adaptive immune response, and the facilitation of APC activation, among others. Extensive research is being undertaken on mRNA-based cancer immunotherapies and uncommon illness therapeutics. Research institutes and business participants are exploring the structural alterations of mRNA and its formulation methods to develop effective mRNA-based pharmaceuticals. In addition, firms operating in the mRNA vaccines and therapies ecosystem are merging industry-academia collaboration to evaluate and create innovative candidates that could assist physicians in treating rare, life-threatening diseases and subtypes of cancer.
North America is the highest revenue contributor and is estimated to exhibit a CAGR of 8% during the forecast period. North America consists primarily of the United States and Canada. Due to numerous important factors, the United States dominated the global market for mRNA vaccines and treatments (by COVID-19 vaccines). These include a rise in funding for developing mRNA-based COVID-19 vaccines, increased pipeline products, established and new pharmaceutical businesses, ultracold manufacturing and supply chains, and a growing awareness of mRNA-based COVID-19 vaccines. Several established mRNA vaccine makers and developers in North America are focused on delivering innovative products to the market to support the nation's immunization strategies.
Large and small market participants engage extensively in R&D and enhance their manufacturing capacities by integrating business synergies and funding operations to capture market share. In June 2020, Moderna, Inc. cooperated with Catalent, Inc. for large-scale, commercial fill-finish manufacture of its innovative mRNA-based COVID-19 vaccine candidate, mRNA-1273, at Catalent's biologics facility in Indiana, U.S. In addition, Moderna, Inc. obtained a grant from the Coalition for Epidemic Preparedness Innovations (CEPI) in January 2020 to develop an mRNA-based COVID-19 vaccine against SARS-CoV-2 infection. In addition, industry participants such as Translate Bio and Arcturus Therapeutics Holdings Inc. are expected to contribute to expanding the North American market.
Europe is anticipated to grow at a CAGR of 2.1% during the forecast period. Between 2026 and 2031, the market for mRNA vaccines and treatments in Europe (excluding COVID-19) is expected to expand rapidly due to several important factors. These factors include but are not limited to rising research and development expenditures related to mRNA vaccines and therapeutic advancements, rising fund infusions for the development of mRNA vaccines and therapeutics for cancer and rare diseases, increasing government initiatives aimed at the adoption of precision medicine, and the presence of legacy and emerging market players. Private and government entities significantly accelerate the development of mRNA vaccines and treatment candidates currently in clinical trials by funding firms. BioNTech SE, for instance, received USD 59.7 million from the European Investment Bank in December 2019 to boost research and development, production, and market access for its most sophisticated mRNA-based medicines.
sales@straitsresearch.com